Clinical trials: TACE
Transarterial Chemoembolization, TACE(Transcatheter Arterial Chemoembolization)
Effectiveness of Enhanced Web-Based Health Education on Self-Care Practices and Quality of Life Among Patients With Hepatocellular Carcinoma Undergoing TACE
This randomized controlled trial aims to evaluate the effectiveness of enhanced web-based health education on self-care practices and quality of life among patients with hepatocellular carcinoma.
- Conditions
- Transarterial Chemoembolization, TACE(Transcatheter Arterial Chemoembolization), Web-based Intervention, Quality of Life
- Trial name
- NCT07825519
- Testing
- Enhanced Web-Based Health Education, Routine Health Education
- Where
- Vietnam
- Volunteers
- 252 people, healthy volunteers welcome
- Sponsor
- University Medical Center Ho Chi Minh City (UMC)
Carcinoma, Hepatocellular
Transcatheter Arterial Chemoembolization With KMG Microsphere Treating Advance-stage Hepatocellular Carinomas
The purpose of the study is to evaluate the effects of Transcatheter Arterial Chemoembolization (TACE) with KMG microsphere in treating advance-stage Hepatocellular Carinoma(HCC).
- Trial name
- TACE-KMG (NCT01393093)
- Testing
- Therapeutic Chemoembolization
- Where
- China
- Volunteers
- 2,840 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatocellular Carcinoma
The LC Bead Trial; Transarterial Chemoembolization of Hepatocellular Carcinoma (HCC)With a Drug-eluting Bead
This study involves the combined use of the FDA approved device, LC Bead and the FDA approved drug, Doxorubicin for the treatment of primary hepatocellular carcinoma (HCC).
- Trial name
- NCT01259024
- Testing
- transarterial chemoembolization using a drug-eluting bead
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Internal Radiation, Advanced Hepatocellular Carcinoma
Targeted Internal Radiation Therapy in Advanced HCC Patients.
The aim of this study is to evaluate the 131I-chTNT-1/B treatment effect and safety of individual therapy using randomized controlled study, in order to acquire the evidence of evidence-based medicine and create a new program of…
- Trial name
- NCT02724267
- Testing
- 131I-chTNT-1/B
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
HCC - Hepatocellular Carcinoma, TACE
OE MRI to Predict Treatment Response After TACE in HCC Patients
To predict response of HCC to TACE using dynamic oxygen-enhanced (dOE)-MRI for assessment of the level of tumor hypoxia before and after treatment.
- Conditions
- HCC - Hepatocellular Carcinoma, TACE, SIRT
- Trial name
- HERO (NCT07617038)
- Testing
- MRI contrast-enhancing agents
- Where
- Canada
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Université de Montréal
HCC - Hepatocellular Carcinoma
Measuring the Density of Iodine in Lipiodol Depositions: Detecting an Invisible Residual Tumor After Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma
ABSTRACT Objective: To detect presence of a residual tumor in patients of hepatocellular carcinoma (HCC) treated with Lipiodol based conventional trans arterial chemoembolization (cTACE) using density measurements on follow-up…
- Trial name
- NCT06602986
- Testing
- TACE
- Where
- Pakistan
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Pak Emirates Military Hospital
Hepatocellular Carcinoma, Liver Cancer
Safety and Efficacy of DEB-TACE Performed With a Novel Reflux-control Microcatheter in Patients With HCC
BACKGROUND: Hepatocellular carcinoma is the fifth most frequent cancer in the world, with a diagnosis of more than 500,000 new cases per year.
- Trial name
- NCT04653701
- Testing
- Chemoembolization with preloaded microparticles 100 micron and reflux control microcatheter
- Where
- Spain
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Juan José Ciampi Dopazo
Hepatocellular Carcinoma
A Trial on SBRT After Incomplete TAE or TACE Versus Exclusive TAE or TACE For Treatment of Inoperable HCC
The trial is a multicentre, prospective, randomised controlled, unblinded, parallel-group superiority trial of SBRT versus standard TAE/TACE for the curative treatment of inoperable HCC treated with a TAE/TACE incomplete cycle.
- Trial name
- NCT02323360
- Testing
- SBRT, TACE
- Where
- Italy
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Istituto Clinico Humanitas
HCC, Tace
Partial Immune-boost TACE in unrEseCTable HCC Patients Under Systemic Treatment
Study Objectives： Atezolizumab (anti-programmed death-ligand 1; anti-PD-L1) combined with bevacizumab (anti-vascular endothelial growth factor; anti-VEGF) or Durvalumab (anti-programmed death-ligand 1; anti-PD-L1) combined with…
- Conditions
- HCC, Tace, Immunotherapy
- Trial name
- EXPECT (NCT07168668)
- Testing
- Transarterial chemoembolization, durvalumab and tremelimumab
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Hepatocellular Carcinoma
A Novel Immunotherapy PD-1 Antiboty to Suppress Recurrence of HCC Combined With PVTT After Hepatic Resection
Hepatic resection is the most effective curative treatment for resectable HCC, whereas frequent recurrence usually impaired the efficacy of hepatic resection and contributed poor survivals.
- Trial name
- NCT03914352
- Testing
- PD-1 antibody, TACE
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Cancer Hospital of Guangxi Medical University
Extrahepatic Cholangiocarcinoma
An Observational Real World Study on the Efficacy and Safety of Toripalimab Injection Combined With TACE in the Treatment of Extrahepatic Cholangiocarcinoma
This is an open-label, single-arm, multicenter phase II clinical study to preliminarily observe and evaluate the efficacy and safety of Toripalimab combined with TACE in the treatment of extrahepatic cholangiocarcinoma.
- Trial name
- NCT05448183
- Testing
- Toripalimab, Gemcitabine,Oxaliplatin
- Where
- China
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Xuhua Duan
Healthy Volunteers
Recruiting Blood Donor With Allogeneic Natural Killer Cell
This study on manufacture of MG4101 (allogeneic natural killer cell) to use for Hepatocellular carcinoma(HCC) after Transarterial Chemoembolization(TACE) will be harvested WBC(white blood cell) and plasma from healthy donors, or…
- Trial name
- NCT02716571
- Testing
- Leukapheresis or Plasmapheresis
- Where
- South Korea
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Hepatocellular Carcinoma
Transarterial Chemoembolization (TACE) With or Without Stereotactic Body Radiotherapy (SBRT) in Hepatocellular Carinoma
Hypothesis: Patients with hepatocellular carcinoma (HCC) have few options if they fail or are unable to undertake surgery, transarterial chemoembolization (TACE) and/or chemotherapy.
- Trial name
- TACERT (NCT03079778)
- Testing
- transarterial chemoembolization, TACE plus RT
- Volunteers
- healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Hepatocellular Cancer
Interest of elastoFRM With Force Measure by MRI on Patients With Hepatocellular Cancer
FORCE project aims to measure actives forces of malignant tumor by magnetic resonance force (FRM). Two main forces are considered as key indicators of therapeutic response and metastatic potential: interstitial force and traction…
- Trial name
- FORCE (NCT02929082)
- Testing
- IRM with a 5-minute- additional sequence to measure FRM
- Where
- France
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hepatocellular Carcinoma
A Trial of Adjuvant Transarterial Chemoembolization (TACE) for Preventing Tumor Recurrence After Liver Resection
The aim of this study is to analyze the therapeutic effect of adjuvant TACE after resection.Patients receiving curative resection (R0) were randomized to postoperative TACE group and no TACE group.
- Trial name
- NCT00820053
- Testing
- epirubicin and lipiodol
- Where
- China
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Hepatocellular Carcinoma
DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma
Transarterial chemoembolization (TACE) based on drug-eluting beads (DEB-TACE) is widely used for unresectable hepatocellular carcinoma (HCC). However, the long-term survival is still low after DEB-TACE treatment.
- Trial name
- NCT04229355
- Testing
- DEB-TACE plus Sorafenib, DEB-TACE plus Lenvatinib, DEB-TACE plus PD-1 inhibitor
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Guangxi Medical University
Intrahepatic Cholangiocarcinoma
D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC
This is a prospective, single-arm, multicenter, phase II trial to evaluate the efficacy and safety of D-TACE-HAIC (GEMOX protocol) in combination with Envafolimab and Lenvatinib for unresectable intrahepatic cholangiocarcinoma.
- Trial name
- NCT06643208
- Testing
- TACE-HAIC, Envafolimab and Lenvatinib
- Where
- China
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Fujian Provincial Hospital
Hepatocellular Carcinoma
Study of Apatinib Combined With TACE in Advance Hepatocellular Carcinoma
the purpose of this study is to evaluate the efficacy and safety of aptinib in patients with advanced HCC
- Trial name
- HCC (NCT03398122)
- Testing
- TACE, Apatinib
- Where
- China
- Volunteers
- 248 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatocellular Carcinoma of the Liver, Subjects Eligible for Liver Transplantation
Bridge to Orthotopic Liver Transplantation (OLT) - Surefire Precision vs Endhole Embolization With DEBTACE
The purpose of this study will be to prospectively evaluate the outcomes of patients with hepatocellular carcinoma (HCC) who undergo DEB-TACE (drug-eluting bead trans-arterial chemoembolization) with the Surefire Precision…
- Trial name
- SPEED (NCT03170869)
- Testing
- Surefire Precision Infusion System
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Hepatocellular Carcinoma
Adjuvant Therapies for Patients With HCC and MVI
Hepatocellular carcinoma (HCC) is a common malignancy, and its incidence is expected to increase in many countries in coming decades.
- Trial name
- A-TACE/S-HCC (NCT02436902)
- Testing
- TACE, Sorafenib, TACE plus sorafenib
- Where
- China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Guangxi Medical University